Search | Clinical Trials Finder

Conditions: Chronic Hepatitis B Virus Infection, Hepatitis B
Interventions: Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more

Conditions: Hepatitis B, Chronic
Interventions: JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil, TAF, ETV; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Hillsborough, New Jersey

Conditions: Hookworm Infections
Interventions: Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, Na-GST-1/Alhydrogel + GLA-AF, Placebo, Albendazole, Necator americanus Larval Inoculum; Biological · Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hepatoma, Advanced Solid Tumor
Interventions: irinotecan and ON 01910.Na, oxaliplatin and ON 01910.Na; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Chronic
Interventions: BI201335, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Baltimore, Maryland • New York, New York + 1 more

Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate; Radiation · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 211
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more

Conditions: Chronic Pain, Low Back Pain
Interventions: Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain, Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT); Combination Product
Lead sponsor: Evon Medics LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Pasadena, Maryland

Conditions: Hepatitis C
Interventions: BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 6
States / cities: Tulepo, Mississippi • New York, New York • Germantown, Tennessee + 3 more

Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
Interventions: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 31 Years
Enrollment: 5,949 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 209
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more

Conditions: Improvement of Wrinkles/Elastosis as Well as General Skin Tone
Interventions: M22 ResurFX, M22 ResurFX and QS; Device
Lead sponsor: Lumenis Be Ltd.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: External automated abdominal binder; Device
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Low Back Pain
Interventions: Chiropractic, Acupuncture; Other
Lead sponsor: Southern California University of Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Whittier, California

Conditions: Hepatitis B, Chronic
Interventions: JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA); Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more

Conditions: Chronic Hepatitis B Virus
Interventions: Stop NA therapy; Other
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years to 67 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
Interventions: Nivolumab, Azacitidine, Post Treatment Surgery; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: Up to 39 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 19 more

Conditions: Crohn Disease
Interventions: infliximab infusion; AZA placebo caps, infliximab (IFX) infusion; azathioprine (AZA) caps, infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Biological · Other · Drug
Lead sponsor: Centocor Ortho Biotech Services, L.L.C.; Industry
Eligibility: 21 Years to 99 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 51
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 48 more

Conditions: Hepatitis B
Interventions: JNJ-56136379, Placebo, NA (ETV or TDF); Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Bakersfield, California • Orlando, Florida • Chicago, Illinois + 4 more

Conditions: Smoking Cessation
Interventions: Nicotine Patch, Counseling, Smartphone, AutoSense; Drug · Behavioral · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Solid Tumor
Interventions: ON 01910.Na, Gemcitabine; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: San Francisco, California • The Bronx, New York

Conditions: Heart Failure, Heart Assist Device, Hyponatremic
Interventions: tolvaptan; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Low Risk Myelodysplastic Syndromes
Interventions: R906289 Monosodium (R289 Na); Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 15
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 12 more

Conditions: Chronic Pain, Low Back Pain
Interventions: Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short burst paradigm, Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long burst paradigm, Computerized Chemosensory-Based Orbitofrontal Cortex Training plus beta caryophyllene (CBOT-Plus), Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT); Combination Product
Lead sponsor: Evon Medics LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Other Benign Neoplasm of Skin, Unspecified
Interventions: Diclofenac Na gel, Eflornithine HCL ointment; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 40 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 3
States / cities: Tucson, Arizona

Conditions: Influenza, Healthy Volunteers
Interventions: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years and older
Enrollment: 1,162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more

Search by objective public record fields.

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)

Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Impact of Synergistic Sequential Treatment (SST)

High Sodium Diet and External Abdominal Compression in POTS

Integrated Chiropractic and Acupuncture Treatment for Low Back Pain

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

The Hepatitis B e-Antigen Negative Disease - Directly Offered Study of Treatment Withdrawal in Patients With e-Antigen Negative Chronic HBV Infection (BeNEG-DO).

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

Applying mHealth to Tobacco-related Health Disparities

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Development and Evaluation of Computerized Chemosensory Based Orbitofrontal Networks Training for Treatment of Pain

Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older